Literature DB >> 3199072

Induction of lymphokine-activated killer-like cells by cancer chemotherapy.

T Kiyohara1, K Taniguchi, S Kubota, S Koga, T Sakuragi, Y Saitoh.   

Abstract

Natural cell-mediated cytotoxicity against NK-resistant target tumor cells was found in the peripheral blood of tumor-bearing patients approximately 1 mo after combined chemotherapy. The recognition specificity of these effector cells was broad and had no restriction. From the experiments of negative selection with mAbs and complements, these newly developed killer cells after chemotherapy were thought to be LAK-like cells. Contribution of these LAK-like cells to the mechanism of action of anticancer drugs remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3199072      PMCID: PMC2189131          DOI: 10.1084/jem.168.6.2355

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice.

Authors:  A Mantovani; W Luini; G Peri; A Vecchi; F Spreafico
Journal:  J Natl Cancer Inst       Date:  1978-11       Impact factor: 13.506

2.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; T Ahmed; L R Weiselberg; N Geller; P S Hollander; H W Herr; P C Sogani
Journal:  J Urol       Date:  1985-03       Impact factor: 7.450

3.  Augmentation of the human immune response by cyclophosphamide.

Authors:  D Berd; M J Mastrangelo; P F Engstrom; A Paul; H Maguire
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

4.  Lymphokine-activated killer cells in mouse bone marrow chimaeras. The relationship to natural killer cells and to alloreactive cytotoxic T cells.

Authors:  M Sihvola
Journal:  Scand J Immunol       Date:  1985-11       Impact factor: 3.487

5.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells.

Authors:  R Suzuki; K Handa; K Itoh; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

6.  Natural killer (NK) cell activity during lymphatic regeneration: early appearance of Thy-1+ NK cells and highly interleukin 2-(IL 2) receptive, Thy-1- cells.

Authors:  M Hurme; M Sihvola
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

7.  Defective repertoire of proliferative T cells during lymphatic regeneration.

Authors:  M Sihvola; M Hurme
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

8.  An exoglycosidase-sensitive triggering site on NK cells which is coupled to transmethylation of membrane phospholipids.

Authors:  T Kiyohara; J W Dennis; R J Boegman; J C Roder
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

9.  Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.

Authors:  G Pizzocaro; L Piva; R Salvioni; F Zanoni; A Milani
Journal:  Cancer       Date:  1985-11-15       Impact factor: 6.860

10.  Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.

Authors:  C Gambacorti-Passerini; L Rivoltini; R Supino; M Rodolfo; M Radrizzani; G Fossati; G Parmiani
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

View more
  5 in total

1.  Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.

Authors:  A Eisenthal; Y Skornick; I Ron; V Zakuth; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

2.  Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.

Authors:  Z Gazit; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

3.  Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.

Authors:  Y Komada; S L Zhang; Y W Zhou; M Hanada; T Shibata; E Azuma; M Sakurai
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.

Authors:  H Onodera; S S Somers; P J Guillou
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

5.  Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.

Authors:  Veit Bücklein; Tina Adunka; Anna N Mendler; Rolf Issels; Marion Subklewe; Jan C Schmollinger; Elfriede Noessner
Journal:  Oncoimmunology       Date:  2016-04-29       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.